NTRK1 and bone neoplasm: Finally, early administration of ARRY-470 (Figure 5), an ATP-competitive selective pan-Trk inhibitor with a nanomolar activity toward TrkA, B and C demonstrated the beneficial effect of Trk inhibition in a mouse model of bone cancer pain [22].